Intercept Pharmaceuticals Stock Forecast - Daily Balance Of Power

ICPTDelisted Stock  USD 10.31  0.16  1.53%   
Intercept Stock Forecast is based on your current time horizon.
  
On June 14, 2023 Intercept Pharmaceuticals had Daily Balance Of Power of (0.40). Balance of Power indicator (or BOP) measures the strength of Intercept Pharmaceuticals market sensitivity to bulls and bears. It estimates the ability of Intercept Pharmaceuticals buyers and sellers to push price to an extreme high or extreme low level. As a result, by monitoring Intercept Pharmaceuticals Balance of Power indicator one can determine a trend of the price direction.
Check Intercept Pharmaceuticals VolatilityBacktest Intercept PharmaceuticalsTrend Details  

Intercept Pharmaceuticals Trading Date Momentum

On June 15 2023 Intercept Pharmaceuticals was traded for  11.82  at the closing time. The top price for the day was 12.06  and the lowest listed price was  11.65 . The trading volume for the day was 1.4 M. The trading history from June 15, 2023 was a factor to the next trading day price decrease. The trading delta at closing time against the next closing price was 1.83% . The trading delta at closing time against the current closing price is 1.50% .
Balance of Power indicator was created by Igor Livshin to predict asset short term price movements or warning signals. If Balance of Power indicator is trended towards the high of its range it will signify that the bulls are in control. On the other hand when the BOP indicator is moving towards the lows of its range it signifies that the bears are in control. If the indicator move from a high positive range to a lower positive range it signifies that the buying pressure is decreasing. Conversely, if the indicator move from a low negative range to a higher negative range it signifies that the selling pressure is decreasing.
Compare Intercept Pharmaceuticals to competition

View Intercept Pharmaceuticals Related Equities

 Risk & Return  Correlation

Intercept Pharmaceuticals Market Strength Events

Market strength indicators help investors to evaluate how Intercept Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Intercept Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Intercept Pharmaceuticals stock market strength indicators, traders can identify Intercept Pharmaceuticals entry and exit signals to maximize returns.

Intercept Pharmaceuticals Risk Indicators

The analysis of Intercept Pharmaceuticals' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Intercept Pharmaceuticals' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting intercept stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Intercept Stock

If you are still planning to invest in Intercept Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intercept Pharmaceuticals' history and understand the potential risks before investing.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing